Compare · ENOV vs EW
ENOV vs EW
Side-by-side comparison of Enovis Corporation (ENOV) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ENOV and EW operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $49.43B, about 36.3x ENOV ($1.36B).
- Over the past year, ENOV is down 28.1% and EW is up 12.5% - EW leads by 40.6 points.
- ENOV has been more active in the news (14 items in the past 4 weeks vs 7 for EW).
- EW has more recent analyst coverage (25 ratings vs 19 for ENOV).
- Company
- Enovis Corporation
- Edwards Lifesciences Corporation
- Price
- $23.67-0.42%
- $85.84-0.14%
- Market cap
- $1.36B
- $49.43B
- 1M return
- -13.20%
- +3.72%
- 1Y return
- -28.10%
- +12.46%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 14
- 7
- Recent ratings
- 19
- 25
Enovis Corporation
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest ENOV
- Enovis Launches Spinamic® Hybrid Scoliosis Brace, Combining Corrective Performance with Improved Wearability for Children and Teens
- Chief Administrative Officer Engert Oliver bought $22,220 worth of shares (1,000 units at $22.22), increasing direct ownership by 2% to 49,640 units (SEC Form 4)
- SEC Form SD filed by Enovis Corporation
- Director Shirley Brady was granted 9,346 shares, increasing direct ownership by 9% to 110,589 units (SEC Form 4)
- Director Lalor Angela S was granted 9,346 shares, increasing direct ownership by 42% to 31,486 units (SEC Form 4)
- Director Ortiz Christine was granted 9,346 shares, increasing direct ownership by 60% to 25,011 units (SEC Form 4)
- Director Bodem Barbara W. was granted 9,346 shares, increasing direct ownership by 63% to 24,201 units (SEC Form 4)
- Director Okala Philip was granted 9,346 shares, increasing direct ownership by 63% to 24,201 units (SEC Form 4)
- Director Wienbar Sharon L was granted 9,346 shares, increasing direct ownership by 29% to 41,946 units (SEC Form 4)
- Director Perfall A Clayton was granted 9,346 shares, increasing direct ownership by 21% to 54,190 units (SEC Form 4)
Latest EW
- SEC Form 3 filed by new insider Mistras Theodora
- SVP, Corporate Controller Dahl Andrew M. sold $48,853 worth of shares (568 units at $86.08), decreasing direct ownership by 4% to 15,334 units (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr sold $2,000,193 worth of shares (23,145 units at $86.42) (SEC Form 4)
- SEC Form SD filed by Edwards Lifesciences Corporation
- CVP, TMTT & Surgical Chopra Daveen sold $126,905 worth of shares (1,500 units at $84.60), decreasing direct ownership by 3% to 44,324 units (SEC Form 4)
- CVP, TAVR Lippis Daniel J. exercised 620 shares at a strike of $72.68 and sold $50,307 worth of shares (620 units at $81.14) as part of a pre-agreed trading plan (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr sold $1,472,678 worth of shares (17,968 units at $81.96), decreasing direct ownership by 30% to 22,798 units (SEC Form 4)
- CEO Zovighian Bernard J converted options into 47,207 shares, covered exercise/tax liability with 26,198 shares, gifted 26,640 shares, received a gift of 26,640 shares and sold $2,833,013 worth of shares (36,351 units at $77.93) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 99,165 units (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr converted options into 13,457 shares and covered exercise/tax liability with 7,469 shares, increasing direct ownership by 22% to 32,766 units (SEC Form 4)
- CVP, TMTT & Surgical Chopra Daveen converted options into 13,583 shares and covered exercise/tax liability with 7,538 shares, increasing direct ownership by 15% to 45,824 units (SEC Form 4)